2021 (v1)
Publication
Background and purpose: Following the commercial availability of nusinersen, there have been a number of new referrals of adults with spinal muscular atrophy (SMA) not regularly followed in tertiary-care centers or enrolled in any disease registry. Methods: We compared demographics and disease characteristics, including assessment of motor and...
Uploaded on: February 14, 2024